CD28 and COVID-19: Other Food and Drug Administration-approved antiinflammatory drugs tested in models of SEB TSS may also be effective, including CTLA4-Ig which can inhibit CD28 costimulation (32), and the mammalian target of rapamycin (mTOR) inhibitor rapamycin (33), which is already in use for COVID-19.